Company intelligence / Profile preview

Quantum-Si

Branford, Connecticut, United Statesquantum-si.com ↗

Ownership: Private
Employees: ~200
Development stage: Other

Overview

Quantum-Si has commercialized the world’s first single-molecule Next Generation Protein Sequencers™, enabling high-resolution protein analysis. Their technology supports applications in biomarker discovery, disease mechanism studies, and drug development. No clinical trial results as they do not develop therapeutics directly.

Therapeutic areas: Other
Modalities: Device
Industry: Protein Biomarker Diagnostics

Partnerships

Collaborations with academic institutions and industry partners; specifics undisclosed

Beyond the preview

Go deeper on Quantum-Si.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Quantum-Si.

Explore the full profile